Patent Review Standard To Get Supreme Court Scrutiny
This article was originally published in The Pink Sheet Daily
Biopharma firms' best chance so far to change Patent Trial and Appeal Board's 'broadest reasonable interpretation' standard doesn't even involve a drug patent.
You may also be interested in...
Amgen exec calls for more informal agency feedback and alignment between review divisions in understanding design methodologies.